Oral Obicetrapib Takes Lipid Lowering to Another Level in Trials

(MedPage Today) -- Obicetrapib provided dramatic reductions in LDL cholesterol, without noticeable side effects, in a phase III trial of high-risk individuals already on maximal lipid-lowering therapy.
In adults with heterozygous familial hypercholesterolemia...